



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/052,121	01/17/2002	Cato T. Laurencin	DRE-0067	1682
7590	06/17/2005		EXAMINER	
Licata & Tyrrell P.C. 66 East Main Street Marlton, NJ 08053			NAFF, DAVID M	
			ART UNIT	PAPER NUMBER
			1651	

DATE MAILED: 06/17/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/052,121	LAURENCIN ET AL.
	Examiner	Art Unit
	David M. Naff	1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 June 2005.
 2a) This action is FINAL. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-3,5 and 6 is/are pending in the application.
 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 1-3,5 and 6 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
 Paper No(s)/Mail Date _____

4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
 5) Notice of Informal Patent Application (PTO-152)
 6) Other: _____.

DETAILED ACTION

The final rejection of 4/1/05 is withdrawn, and prosecution on the merits is reopened in view of new grounds of rejection below.

A response of 6/7/05 presented arguments supported by a
5 Declaration of Dr. Cato T. Laurencin.

Claims examined on the merits are 1-3, 5 and 6, which are all claims in the application.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

10 ***Claim Rejections - 35 USC § 103***

Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over Starling et al (6,210,715 B1) in view of Crotts et al (newly applied).

The claim is drawn to scaffold for tissue engineering comprising
15 biodegradable polymer-based hollow microcarriers with a density equal to or less than water bonded together into an interconnected, three dimensional scaffold.

Starling et al disclose microcarriers (also referred to as microspheres or microbeads) that can be used for cell culture (col 4, 20 lines 32-35, col 5, lines 1-7 and col 6, lines 32-35), or as an implant as a carrier of a pharmaceutical agent (col 9, lines 15 and 22, and col 9, line 57). The microspheres can be hollow, and be bonded together to form an aggregate of bonded together hollow microspheres (Figure 1-1 (1.4)). The hollow microspheres have a 25 density of less than 1 gm/cc (col 6, line 54), and are bonded together

Art Unit: 1651

by coating with calcium phosphate (CaP) and sintering to provide an aggregate having a density of about 1.00-1.12 gm/cc (col 6, line 60), preferably about 1.00-1.06 gms/cc (col 4, line 58). The hollow microspheres are made of a substrate, which can be calcium phosphate, 5 glass, other oxide ceramics or polymers, proteinaceous materials or composite materials (col 5, line 66 to col 6, line 2). When the substrate material is polymeric or proteinaceous, bonding together of the hollow microspheres can involve heating the substrate material to soften the surface (col 6, lines 44-46). Polymeric/organic substrate 10 materials for preparing the hollow microsphere include dextran, polyethylene, polypropylene, polystyrene, polyurethane and collagen (col 17, lines 36-39).

Crotts et al disclose preparing hollow microspheres composed of poly(D,L-lactic-co-glycolic acid) (PLGA) (page 91, abstract) that can 15 be used as a carrier for drug delivery by encapsulating a drug (page 104, right col, lines 1-11). Poly(D,L-lactic acid) and its copolymers with glycolic acid are used as microsphere material due to their versatile biodegradability and biocompatibility (page 91, left col, under "Introduction"). The microspheres are prepared (page 93, left 20 col, under "Microsphere preparation") by adding a water phase (with or without BSA (blood serum albumin)) to methylene chloride containing PLGA, generating an emulsion by ultrasonication, adding the emulsion to a PVA/PBS solution while being magnetically stirred, and continuing stirring for 2-3 h to permit evaporation of solvent. The microspheres

Art Unit: 1651

are collected by centrifugation, washed and lyophilized, and size distribution is measured by using a series of stainless steel meshes.

It would have been obvious to use as the polymeric hollow microspheres of Starling et al, the hollow microspheres made from PLGA disclosed by Crotts et al to obtain the property of PLGA having 5 versatile biodegradability and biocompatibility as disclosed by Crotts et al. It would have been expected the PLGA hollow microspheres can be bonded together to form an aggregate of hollow microspheres by procedures disclosed by Starling et al. The aggregate when shaped as 10 disclosed by Starling et al (col 9, lines 50-58) will be a scaffold as presently claimed.

Claim Rejections - 35 USC § 103

Claims 2, 3, 5 and 6 are rejected under 35 U.S.C. 103(a) as being unpatentable over the references as applied to claim 1 above, and 15 further in view of Spaulding (6,001,643) and Granet et al (AJ on 1449).

Claims 2 and 3 require the scaffold of claim 1 to be seeded with cells via culturing *in vitro* in a rotating bioreactor.

Claims 5 and 6 require a method of generating tissue by seeding 20 the scaffold of claim 1 with cells that produce the tissue, and culturing the seeded cells in a rotating bioreactor.

Starling et al and Crotts et al are described above.

Spaulding discloses culturing cells in a roller bottle for 25 implanting to produce tissue. Microcarrier beads having densities less than the cell culture medium can be used for cell attachment to

Art Unit: 1651

constrain tissue constructs to the area surrounding the annular axis and away from the cylinder wall of the bottle (col 16, lines 25-30).

Granet et al disclose culturing osteoblastic cells on microcarriers in a rotating-wall vessel (page 514, section 2.1.2).

5 When preparing the aggregate of bonded together hollow microspheres of Starling et al using hollow microspheres disclosed by Crotts et al as set forth above, it would have been obvious to use the aggregate for cell culture as suggested by Starling et al, and carry out cell culture in a roller bottle as disclosed by Spaulding or in a 10 rotating-wall vessel as disclosed by Spaulding since these culturing techniques are intended for culturing cells on a carrier. It would have been further obvious to provide the aggregate with a density less than that of water as suggested by Spaulding so the aggregate will surround the axis away from the wall. Culturing cells such as 15 osteoblast cells would have been obvious when the function of these cells is desired.

Response to Arguments

Applicants' arguments and declaration in support thereof are moot in view of the new grounds of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David M. Naff whose telephone number is 571-272-0920. The examiner can normally be reached on Monday-Friday 9:30-6:00.

Art Unit: 1651

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 751-273-8300.

5 Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For 10 more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



David M. Naff
Primary Examiner
Art Unit 1651

15

DMN
6/15/05